Suppr超能文献

接受经皮冠状动脉介入治疗患者的出血并发症

Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention.

作者信息

Galli Mattia, Laborante Renzo, Andreotti Felicita, Vergallo Rocco, Montone Rocco Antonio, Iaconelli Antonio, Trani Carlo, Burzotta Francesco, Crea Filippo, D'Amario Domenico

机构信息

Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, 00168 Rome, Italy.

Department of Cardiology, Maria Cecilia Hospital, GVM Care & Research, 48033 Cotignola, Italy.

出版信息

Rev Cardiovasc Med. 2022 Aug 15;23(8):286. doi: 10.31083/j.rcm2308286. eCollection 2022 Aug.

Abstract

Percutaneous coronary intervention (PCI) is considered a relatively safe procedure associated with low rates of complications, but is inevitably associated with short and mid-to-long term increased bleeding risk. Besides the short term risk associated with the arterial access to perform PCI, enhanced bleeding risk persists for several months, given the need for antithrombotic therapy to prevent procedure-related thrombotic complications as well as ischemic recurrences. Bleeding is a powerful harbinger of adverse outcomes. This awareness has fuelled intense research on bleeding reduction strategies, including new PCI devices and techniques as well as new medications and antithrombotic regimens. We here review the mechanisms and prevalence of bleeding in PCI patients, discuss the available evidence from a practical point of view, and explore future perspectives on how to treat and prevent bleeding complications in these patients.

摘要

经皮冠状动脉介入治疗(PCI)被认为是一种相对安全的手术,并发症发生率较低,但不可避免地与短期及中长期出血风险增加相关。除了与进行PCI的动脉通路相关的短期风险外,鉴于需要抗血栓治疗以预防手术相关的血栓并发症以及缺血复发,出血风险会持续数月。出血是不良结局的有力预兆。这种认识推动了对减少出血策略的深入研究,包括新型PCI设备和技术以及新型药物和抗血栓方案。我们在此回顾PCI患者出血的机制和发生率,从实际角度讨论现有证据,并探讨未来如何治疗和预防这些患者出血并发症的前景。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b241/11266963/30ffc5db77d8/2153-8174-23-8-286-g1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验